Welcome to our dedicated page for AUTOLUS THERAPEUTICS PLC SEC filings (Ticker: AUTL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical-stage biotech filings can run hundreds of pages packed with trial endpoints, cash-burn tables, and complex risk factors. Autolus Therapeutics PLC is no exception鈥攅ach disclosure tracks the progress of its engineered T-cell programs and the funding that keeps them moving. If you have ever searched for "Autolus Therapeutics SEC filings explained simply" or wondered which section shows latest Phase II data, this page is built for you.
Stock Titan鈥檚 AI reads every document the moment it hits EDGAR, then serves concise explanations you can act on. Whether it鈥檚 an Autolus Therapeutics annual report 10-K simplified that pinpoints R&D spend, or an Autolus Therapeutics quarterly earnings report 10-Q filing highlighting cash runway, our summaries surface the metrics biotech investors follow. AG真人官方-time alerts flag "Autolus Therapeutics Form 4 insider transactions real-time" so you can gauge executive confidence before pivotal trial readouts.
Looking for something specific? Our coverage includes:
- Form 4: Track every "Autolus Therapeutics insider trading Form 4 transactions" and spot patterns in executive stock activity.
- 8-K: Get "Autolus Therapeutics 8-K material events explained" within minutes鈥攊deal when new clinical data or financing news breaks.
- 10-K & 10-Q: Dive into "Autolus Therapeutics earnings report filing analysis" without wading through jargon.
- DEF 14A: See "Autolus Therapeutics proxy statement executive compensation" parsed into clear tables.
Use our platform for "understanding Autolus Therapeutics SEC documents with AI"鈥攆rom dilution risk to partnership milestones. Save hours, monitor "Autolus Therapeutics executive stock transactions Form 4", and stay ahead of the next breakthrough.
Autolus Therapeutics plc reported the first commercial product revenue following U.S. launch of AUCATZYL: $20.9 million in Q2 2025 and $29.9 million for the six months ended June 30, 2025, all recorded in the U.S. via Cardinal Health.
The company recorded a quarterly net loss of $47.9 million and a six-month loss of $118.1 million (basic and diluted loss per share $0.18 and $0.44, respectively). Cash and cash equivalents were $123.8 million and marketable securities $330.5 million at June 30, 2025; management states these balances are sufficient to fund operations for at least 12 months from issuance.
Key balance-sheet items include accounts receivable $26.6 million, inventories $23.9 million (with $2.4 million reserves), and a significant liabilities balance for future royalties and milestones of $250.6 million. The company disclosed FDA approval and U.S. commercial launch of AUCATZYL, MHRA conditional authorization in April 2025, and EU approval in July 2025.
Autolus Therapeutics announced it has released its financial results for the quarter ended June 30, 2025 and provided a corporate update. The company furnished a press release (Exhibit 99.1) and an updated corporate presentation (Exhibit 99.2) that it will use in a conference call; both exhibits are expressly noted as furnished rather than filed.
The 8-K clarifies that the information in the exhibits is not subject to Section 18 liabilities and is not incorporated by reference into other filings unless specifically stated. The form text does not include the underlying financial tables, revenue, expense or cash metrics, so detailed figures and operational commentary must be obtained from the attached Exhibit 99.1 and Exhibit 99.2.
Autolus Therapeutics (Nasdaq:AUTL) filed a Form 8-K reporting the results of its 26 June 2025 Annual General Meeting.
All seven ordinary resolutions passed, including:
- Adoption of the 2024 Annual Report (219.8 M for; 0.1 M against).
- Approval of the directors鈥� remuneration report (216.0 M for; 4.3 M against).
- Approval of the directors鈥� remuneration policy (203.4 M for; 16.9 M against).
- Re-appointment of Ernst & Young LLP as auditors (220.3 M for).
- Re-election of directors Dr R. Iannone and Dr R. Rao.
- Adoption of a new Employee Share Purchase Plan authorizing up to 3 million shares.
MAK Capital Fund LP, MAK Capital One L.L.C., and Michael A. Kaufman have disclosed a passive ownership stake in Autolus Therapeutics plc (NASDAQ: AUTL) via Schedule 13G. The group reports beneficial ownership of 15,408,638 American Depositary Shares (ADS), equal to 5.8 % of the company鈥檚 266,141,411 ordinary shares/ADS outstanding as of 7 May 2025. All voting and dispositive authority over the shares is held on a shared basis; none is held solely by any individual entity. MAK Capital Fund is organized in Bermuda, while MAK Capital One L.L.C. and Mr. Kaufman are U.S.-based (Delaware). The filing is made under Rule 13d-1(c), indicating the stake is passive rather than activist; the certification expressly states the securities were not acquired to influence control of the issuer. The event triggering the filing occurred on 17 June 2025, and signatures were executed on 25 June 2025.
The disclosure is material because it crosses the 5 % threshold that requires public reporting, signaling meaningful institutional interest. However, the absence of sole voting power and the passive filing status reduce the likelihood of immediate governance changes. Investors may view the stake as a constructive vote of confidence in Autolus鈥� long-term prospects without signaling imminent strategic pressure.
FAQ
What is the current stock price of AUTOLUS THERAPEUTICS PLC (AUTL)?
What is the market cap of AUTOLUS THERAPEUTICS PLC (AUTL)?
